Research ArticleClinical Studies

Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus

TOSHIYASU OJIMA, MIKIHITO NAKAMORI, MASAKI NAKAMURA, MASAHIRO KATSUDA, KEIJI HAYATA, TOMOYA KATO, JUNYA KITADANI, HIROTAKA TABATA, AKIHIRO TAKEUCHI, MAKOTO IWAHASHI and HIROKI YAMAUE
Anticancer Research February 2016, 36 (2) 829-834;

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Treatment summary. DCF: Docetaxel + cisplatin + fluorouracil; CF: cisplatin + fluorouracil; CRT: chemoradiotherapy.

  • Figure 2.
    Figure 2.

    Kaplan–Meier estimates of relapse-free survival (a) and overall survival (b). The 2-year relapse-free survival rate for patients in the docetaxel with cisplatin plus fluorouracil (DCF) group was 48.9% and that for patients in the cisplatin plus fluorouracil (CF) group was 39.3%. The 2-year overall survival rate for patients in the DCF group was 60.0% and that for patients in the CF group was 57.1%.

Tables

  • Table I.
  • Table II.
  • Table III.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus
TOSHIYASU OJIMA, MIKIHITO NAKAMORI, MASAKI NAKAMURA, MASAHIRO KATSUDA, KEIJI HAYATA, TOMOYA KATO, JUNYA KITADANI, HIROTAKA TABATA, AKIHIRO TAKEUCHI, MAKOTO IWAHASHI, HIROKI YAMAUE
Anticancer Research Feb 2016, 36 (2) 829-834;
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords